Pharmaceutical patent analyst最新文献

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

The patent introduces a class of agents that target amyloid aggregation, and subsequently, reduce amyloid β-oligomer neurotoxicity. The class encompasses sulfopropanoic acid derivatives and is represented by tramiprosate and its prodrug ALZ-801 (valiltramiprosate). Clinical trials showed that ALZ-801 oral tablet is well tolerated and showed superior pharmacokinetic properties in healthy volunteers and Alzheimer's disease (AD) patients. Results from phase II & III trials of ALZ-801 in early AD have provided evidence of efficacy and to adjudicate the role of amyloid β-oligomers in AD pathogenesis. The confirmatory APOLLOE4 phase III trial of ALZ-801 in APOE4/4 homozygotes with early AD has been initiated. If ALZ-801 is approved, it will be among the first oral disease-modifying drugs for AD.

Poly (lactic-co-glycolic acid) (PLGA) is a highly efficient biodegradable polymeric nanoparticle (NP). Owing to its low toxicity, controlled and sustained release qualities, and biocompatibility with tissue and cells, the US FDA has approved its usage in drug delivery systems. The manufacturing and characterization techniques, surface changes, encapsulation of anticancer medicines, active or passive tumor targeting, and various PLGA nanoparticle release methods have been explored in the research arena in the past decade and patents have been filed across the globe. This review covers nanotechnology-backed PLGA patent literature for various types of cancers available on distinguished and eminent patent databases like 'Espacenet' and 'Patent Scope' ranging within a time frame from 2008 to 2024. This review is the first ever reported compilation of the state-of-the-art patent-based literature in PLGA nanoparticles. This review will pave a path for researchers of the present era and future, to understand the research landscape in PLGA nanoparticles and cancer therapy and pave a path for further connective research in the arena of PLGA-based nanoparticles and cancer formulation development.

Obviousness-type double patenting is allowed only in the US, but only if a terminal disclaimer and the same ownership are made for the expiry of the patent. Historically, this provision has hampered the entry of generic and biosimilar drugs due to the legal complexity and cost burden of resolving patent thickets accumulated by the originator companies. The United States Patent and Trademark Office (USPTO) proposed a change in the ruling in March 2024 to avoid double patenting if the patent to which it is tied in terminal disclaimer has any claims that have been invalidated as anticipated or obvious. This rule change aimed to promote innovation and competition by deterring strategies that leverage multiple patents for obvious variants to obstruct competitors. However, after receiving 349 comments on the proposed rule change, the USPTO withdrew its plan in December 2024 despite most comments favoring it. In a contrary move, the USPTO secured a court ruling that the terminal disclaimers do not apply to extended patent expiry due to the failure of the USPTO to prosecute a patent on a timely basis. The double patenting must end to enable more affordable generic and biosimilar drugs.

The oxadiazole derivatives are part of the azole family and have drawn significant interest in medicinal chemistry due to their wide range of biological activities and promising pharmacological profiles. This patent spotlight highlights the developments of the oxadiazole-based compounds reported between 2020 and 2024, with applications in treating diseases such as cancer, bacterial infections, metabolic disorders, and neurodegenerative conditions. These compounds act through various mechanisms, including enzyme inhibition, receptor modulation, and disruption of microbial and cancer cell pathways. Their structural flexibility allows for the design of novel molecules targeting specific therapeutic areas. The spotlight on these recent patents underscores oxadiazole derivatives' growing importance in drug discovery, offering potential advancements in efficacy and safety for future therapeutic agents.

Introduction: Since CD38 is a protein expressed at high levels in multiple myeloma cells, it is an ideal target for antibody design for treatment.

Areas covered: Patent US11905332, which describes two anti-CD38/CD28 bispecific antibodies (bsAb6031 and bsAb7945) with the potential for the treatment of multiple myeloma, was evaluated. The results described in the patent show that the anti-CD38/CD28 bispecific antibodies caused elevated in vitro cytotoxicity in tumor cells through increased proliferation of CD4+ and CD8+ cells, and the release of IFN-γ, IL-2, and TNF-α, as well as efficacy in a mouse model of multiple myeloma.

Expert opinion: Anti-CD38/CD28 bispecific antibodies have the potential to be used alone or in combination with other antibodies, including anti-BCMA/CD3 antibodies, for the treatment of multiple myeloma.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Theranostics represents the state-of-the-art in precision oncology treatment, and is gaining momentum because of the potential to help improve outcomes for even late-stage cancer patients. Pairs of identical (or very similar) molecules are labeled with both diagnostic and therapeutic radionuclides, and used to both image and treat cancer. The FDA approval and commercialization of theranostics for neuroendocrine tumors and prostate cancer has spurred development of new theranostics as well as significant venture and pharma investment, such that both academic medical centers and companies are working to advance the field. One theranostic target of interest is the Fibroblast Activation Protein (FAP) because its expression in many different tumor types offers potential for a pan-cancer theranostic. In this Patent Spotlight, we present the first analysis of patents issued for FAP-targeting radiopharmaceuticals, providing perspective on current trends and challenges as well as future directions.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.